Dynavax Pops With CDC Recommendation

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Dynavax Pops With CDC Recommendation

© Thinkstock

Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain early on Wednesday after the company announced that it received a recommendation from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Essentially the ACIP voted unanimously in favor of including Heplisav-B on its list of recommended products for use to vaccinate adults against hepatitis B. Heplisav-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Ultimately, the receipt of the ACIP recommendation is a key step in providing patients with broad access to Heplisav-B. Medical policies of many insurance plans and institutions require ACIP recommendation before a vaccine is covered or available to their patients.

Dynavax commercially launched Heplisav-B in the United States in January 2018, and it announced Tuesday that the field sales team will begin actively selling Heplisav-B next week.

[nativounit]

Eddie Gray, CEO of Dynavax, commented:

With the ACIP’s recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals. Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults.

Shares of Dynavax were last seen up about 2% at $17.65 on Wednesday, with a consensus analyst price target of $29.00 and a 52-week range of $3.90 to $24.45.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

DELL Vol: 42,366,555
NTAP Vol: 15,911,807
NOW Vol: 68,243,561
IBM
IBM Vol: 28,527,546
HPE Vol: 86,996,387

Top Losing Stocks

CTRA Vol: 73,319,495
CLX Vol: 4,744,001
RMD Vol: 3,526,686
INTC Vol: 191,680,425
SWKS Vol: 5,407,806